CrossRef Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study Jung Sun Kim, Jeffrey Wong, SanChi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon Liver International .2026;[Epub] CrossRef Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma Xianggang Gou, Zhongzheng Zhou, Yuehua Wang, Henye Yuan, Ziyao Wang, Jie Chen, Wei Yan, Haisheng Wang, Jia Yan Biochemical Pharmacology .2026
Measuring inconsistency in meta-analyses
139 , and Henderson et al
I don't know if it's an unintended side effect of the meds, or it comes with the weight loss or both, but I'm thrilled that I don't spend all day every day with my body hurting anymore
10.1002/ana.10784
The TRIUMPH trials and long-term cardiovascular outlook Understanding the long-term cardiovascular safety of retatrutide requires looking at the broader clinical trial program being conducted by Eli Lilly